Susan Serrao

Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering clinical-stage biotech company developing innovative therapies for inflammatory diseases, announces a strategic collaboration with Prenosis®, a leader in […]

Fast Track status accelerates regulatory pathway for BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. Second Fast Track designation in recent months highlights broad potential of rhu-pGSN across multiple diverse inflammation-driven conditions. NORTH BRUNSWICK, N.J., August 20, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.  Global Phase 2b clinical trial underway evaluating rhu-pGSN for the treatment of moderate to severe ARDS.  NORTH BRUNSWICK, N.J., June 17, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech

Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of  inflammatory diseases, to be studied as an intervention for the negative outcomes of decompression in SCUBA Divers. NORTH BRUNSWICK, N.J., June 10, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for acute and chronic inflammatory

600-patient study to assess efficacy of rhu-pGSN,  an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens.  Results from this landmark study expected to inform therapeutic strategies beyond ARDS, positioning rhu-pGSN as a promising intervention across a spectrum of acute and chronic inflammatory diseases.  NORTH BRUNSWICK, N.J., May 6, 2025

Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025.  COO Valerie Ceva will present at MedInvest Biotech & Pharma Investor Conference in NYC on March 27, 2025.  NORTH BRUNSWICK, N.J., March 18, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics,